下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGinkgolic AcidCat. No.: HY-N0077CAS No.: 22910-60-7Synonyms: Ginkgolic acid (15:1); Ginkgolic acid I; Romanicardic acid分式: CHO分量: 346.5作靶點(diǎn): E1/E2/E3 Enzyme作通路: Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solven
2、t -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (288.60 mM)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.75 mg/mL (7.94 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oil1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.75 mg/mL (7.94 mM); Clear solutionBIOLOGICAL ACTIV
3、ITY物活性 Ginkgolic Acid種天然化合物, 在體外實(shí)驗(yàn)中抑制 SUMOylation 的 IC50 為3.0 M。體外研究 Ginkgolic acid inhibits the in vitro SUMOylation of RanGAP1-C2 with the IC50 values of 3.0 M. The level ofSUMOylated p53 is markedly reduced by the ginkgolic acid treatment. Importantly, ginkgolic acid does notaffect protein ubiqui
4、tination in cells. Ginkgolic acid inhibits the binding between E1 and GA-BODIPY in adose-dependent manner 1. Ginkgolic acid (31.2 g/mL) inhibits HIV protease activity by 60%, comparedwith the negative control, and the effect is concentration-dependent. Ginkgolic acid treatment (50 and 100 g/mL) effe
5、ctively inhibits HIV infection in human PBMC cells. Ginkgolic acid at the concentrations up to 150 g/mL does not cause any significant cytotoxicity in Jurkat cells 2. GA only inhibits the growth of tumorogeniccell lines in a both dose- and time-dependent manner. Tumor cells are treated with GA for 7
6、2 h, 70.534.54%Hep-2 and 63.57.2% Tca8113 cells are retarded at GO/G1 phase, and the percentage of apoptosis is40.41.58 and 38.41.7%, respectively. GA-treated activated caspase-3 downregulates the expression ofanti-apoptotic Bcl-2 protein and upregulates the expression of pro-apoptotic Bax protein,
7、eventually leadingto a decrease in the Bcl-2/Bax ratio in tumor cellsin human PBMC cells. Ginkgolic acid at the concentrationsup to 150 g/mL does not cause any significant cytotoxicity in Jurkat cells 3.PROTOCOLCell Assay 2 Jurkat cells (106 cells/mL) are cultured in the RPMI medium with or without
8、different concentrations ofginkgolic acid for 48 hours to test the cytotoxicity of ginkgolic acid. The cytotoxicity of ginkgolic acid isdetermined using a tetrazolium compound (MTS) and an electron coupling reagent (PMS). MTS is chemicallyreduced by cells into formazan, which is soluble in the tissu
9、e culture medium. The measurement of theabsorbance of the formazan can be carried out using 96 well microplates at 492 nm. Since the production offormazan is proportional to the number of living cells, the intensity of the produced color is a good indicationof the viability of the cells.MCE has not
10、independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Toxicol Appl Pharmacol. 2018 Apr 15;345:1-9.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Fukuda I, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E
11、1-SUMO intermediate. Chem Biol. 2009 Feb27;16(2):133-40.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE2. L JM, et al. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med Sci Monit. 2012 Aug;18(8):BR293-298.3. Zhou C, et al. Antitumor effects of ginkgolic acid in human ca
12、ncer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio toinduce apoptosis. Chemotherapy. 2010;56(5):393-402.4. Qiu F, et al. Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice.Toxicol Appl Pharmacol. 2018 Apr 15;345:1-9.McePdfHeightCaution:
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024年高標(biāo)準(zhǔn)地基買(mǎi)賣(mài)合同規(guī)范與市場(chǎng)動(dòng)態(tài)3篇
- 成都醫(yī)學(xué)院《黨政公文寫(xiě)作》2023-2024學(xué)年第一學(xué)期期末試卷
- 成都師范學(xué)院《職業(yè)衛(wèi)生與職業(yè)醫(yī)學(xué)2》2023-2024學(xué)年第一學(xué)期期末試卷
- 成都師范學(xué)院《社會(huì)保險(xiǎn)理論與實(shí)務(wù)》2023-2024學(xué)年第一學(xué)期期末試卷
- 成都理工大學(xué)工程技術(shù)學(xué)院《復(fù)音樂(lè)基礎(chǔ)》2023-2024學(xué)年第一學(xué)期期末試卷
- 成都航空職業(yè)技術(shù)學(xué)院《行業(yè)發(fā)展趨勢(shì)研究》2023-2024學(xué)年第一學(xué)期期末試卷
- 基于AI智能的智慧博物館解決方案
- 2025年度水庫(kù)承包合同協(xié)議書(shū)(水庫(kù)水資源優(yōu)化配置)6篇
- 2024汽車(chē)企業(yè)綠色生產(chǎn)改造合同
- 2024水泵采購(gòu)合同范本
- 200句搞定中考英語(yǔ)詞匯
- 2024年型材切割機(jī)市場(chǎng)需求分析報(bào)告
- 二型糖尿病足
- 汽車(chē)文化教案(汽車(chē)發(fā)展史)
- 土木工程認(rèn)識(shí)實(shí)習(xí)報(bào)告
- 服務(wù)區(qū)安全生產(chǎn)培訓(xùn)
- 兒童顱內(nèi)腫瘤的診斷與手術(shù)治療
- IATA區(qū)域的劃分(TC1區(qū))
- 醫(yī)院對(duì)賬平臺(tái)技術(shù)方案
- 山茶油知識(shí)普及課件
- 圖形創(chuàng)意共生圖形實(shí)訓(xùn)+講授
評(píng)論
0/150
提交評(píng)論